China-based Alphamab Oncology (HKG: 9966) has released data snapshots from clinical studies for two of its pipeline candidates, KN046 and KN026, at the European Society for Medical Oncology (ESMO) Congress 2023. These bispecific antibodies (BsAbs) are being evaluated for their efficacy and safety in treating various types of cancers, with updates from several clinical trials provided at the congress.
KN046: Dual-Targeting Bispecific Antibody
KN046, a bispecific antibody targeting both programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), is the subject of around 20 clinical studies. These studies cover non-small cell lung cancer (NSCLC), pancreatic, liver, and breast cancers among a total dozen tumor types. The data presented at ESMO included updates from four clinical trials, showcasing KN046’s significant therapeutic effects and overall good safety profile.
KN026: Next-Generation HER2-Targeted BsAb
KN026, a potential next-generation HER2-targeted BsAb, has demonstrated anti-tumor activities in HER2 positive breast cancer in multiple studies. It is said to be superior to the combination of trastuzumab and pertuzumab, with a higher affinity and a good safety and tolerability profile.
Clinical Trial Highlights
- The KN046-201 study evaluated the efficacy and safety of KN046 in patients with metastatic NSCLC who had previously failed EGFR-TKI treatment, showing an objective response rate (ORR) of 26.9% and a disease control rate (DCR) of 84.6%.
- In studies for KN046 in metastatic NSCLC patients who have failed previous immunotherapy, the drug demonstrated good tolerance and significant therapeutic effects.
- The Phase II KN046-209 study evaluated the efficacy and safety of KN046 combined with axitinib in the first-line treatment of advanced NSCLC, with an ORR of 58.6%.
- The Phase II KN046-205 study evaluated the safety and efficacy of KN046 in the treatment of recurrent/metastatic thymic cancer patients, with an ORR of 15.6%.
KN026 Study Outcomes
- The KN026-201 study evaluated the efficacy and safety of KN026 combined with docetaxel in first-line treatment of HER2-positive recurrent or metastatic breast cancer, showing an ORR of 76.4% and a DCR of 100%.
- The KN026-208 study evaluated the new adjuvant treatment of KN026 combined with docetaxel for HER2 positive early or locally advanced breast cancer, with a total pathological complete response (tpCR) rate of 56.7%.-Fineline Info & Tech
